000276325 001__ 276325
000276325 005__ 20250216000752.0
000276325 0247_ $$2doi$$a10.1016/j.bbr.2025.115437
000276325 0247_ $$2pmid$$apmid:39855473
000276325 0247_ $$2ISSN$$a0166-4328
000276325 0247_ $$2ISSN$$a1872-7549
000276325 0247_ $$2altmetric$$aaltmetric:173681325
000276325 037__ $$aDZNE-2025-00288
000276325 041__ $$aEnglish
000276325 082__ $$a610
000276325 1001_ $$aHansen, Niels$$b0
000276325 245__ $$aLongitudinally persisting KCNA2-autoantibodies in mild amnestic dementia with Alzheimer´s pathology - Report and literature review.
000276325 260__ $$aAmsterdam$$bElsevier$$c2025
000276325 3367_ $$2DRIVER$$aarticle
000276325 3367_ $$2DataCite$$aOutput Types/Journal article
000276325 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1739354294_23637
000276325 3367_ $$2BibTeX$$aARTICLE
000276325 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000276325 3367_ $$00$$2EndNote$$aJournal Article
000276325 520__ $$aNeural autoantibodies are being increasingly detected in conjunction with neurodegenerative dementias such as Alzheimer's disease dementia (AD), yet their significance is not well clarified. In this case report, we report the previously unreported long-lasting persistence of potassium voltage-gated channel subfamily A member 2 (KCNA2) antibodies in biomarker-supported AD.We report on a 77-year-old, male patient evaluated in our outpatient memory clinic of the Department of Psychiatry and Psychotherapy, University Medical Center Göttingen. Neuropsychological test results and autoantibody testing in serum over a period of 4-5 years is provided.Our patient exhibited mild dementia syndrome and was diagnosed with AD on the basis of a prototypical biomarker profile (reduced Aβ42/40 ratio and elevated p-tau181 protein in cerebrospinal fluid). Within a 5-year follow-up with regular visits to our memory clinic, we observed a nearly stable neuropsychological profile of mild, amnestic variant dementia that did not noticeably progress. KCNA2 autoantibodies were also detectable in serum over 4 years with increasing titers over time. Combined anti-dementia therapy with donepezil, multimodal therapy including non-pharmacological cognitive therapy, and immunotherapy with intravenous methylprednisolone was carried out as an individual treatment approach.KCNA2 autoantibody persistence in biomarker-supported AD does not necessarily trigger a poor outcome in the long-term, as cognitive impairment did not progress subsequently. At the same time, mild immunotherapy did not result in less immunoreactivity in conjunction with the detection of KCNA2 autoantibodies. This detection of KCNA2 autoantibodies in AD could provide indices of a potentially benign long-term AD course that should be further evaluated in studies.
000276325 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000276325 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000276325 650_7 $$2Other$$aAlzheimer´s pathology
000276325 650_7 $$2Other$$aAutoimmunity
000276325 650_7 $$2Other$$aDementia
000276325 650_7 $$2Other$$aKCNA2 autoantibodies
000276325 7001_ $$aTeegen, Bianca$$b1
000276325 7001_ $$aHirschel, Sina$$b2
000276325 7001_ $$aFox, Janosch$$b3
000276325 7001_ $$aFitzner, Dirk$$b4
000276325 7001_ $$0P:(DE-2719)2811317$$aWiltfang, Jens$$b5$$udzne
000276325 7001_ $$aBartels, Claudia$$b6
000276325 773__ $$0PERI:(DE-600)2013604-3$$a10.1016/j.bbr.2025.115437$$gVol. 482, p. 115437 -$$p115437$$tBehavioural brain research$$v482$$x0166-4328$$y2025
000276325 8564_ $$uhttps://pub.dzne.de/record/276325/files/DZNE-2025-00288.pdf$$yOpenAccess
000276325 8564_ $$uhttps://pub.dzne.de/record/276325/files/DZNE-2025-00288.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000276325 909CO $$ooai:pub.dzne.de:276325$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000276325 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811317$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000276325 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000276325 9141_ $$y2025
000276325 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBEHAV BRAIN RES : 2022$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000276325 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-18
000276325 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-18
000276325 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000276325 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-18$$wger
000276325 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-18
000276325 9201_ $$0I:(DE-2719)1410006$$kAG Wiltfang$$lMolecular biomarkers for predictive diagnostics of neurodegenerative diseases$$x0
000276325 980__ $$ajournal
000276325 980__ $$aVDB
000276325 980__ $$aUNRESTRICTED
000276325 980__ $$aI:(DE-2719)1410006
000276325 9801_ $$aFullTexts